Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether his Department plans to modify the labelling of topical steroid medications to include clear warnings against over-use.

The Medicines and Healthcare products Regulatory Agency (MHRA) is conducting a review of topical steroid withdrawal. The review is discussing alterations to labelling, guidance and communications with health care professionals. We have consulted on these topics with healthcare experts in the field including those in the National Health Service, patient representatives and other stakeholders. We are considering updates to the product information and further communications to health care professionals and the MHRA expects to issue more information on this in the next few months.